NCT05165251招募中4 期
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2022年1月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Change in mean office systolic blood pressure after 12-month treatment from baseline in each group
研究概览
简要总结
- Study name: Blood Pressure and Lipids Reduction in High Risk Elderly Patients with Isolated Systolic Hypertension.
- Medicine: amlodipine/atorvastatin tablet (5mg/10mg) and amlodipine (5mg).
- Rationale: Because of its extremely high prevalence in older adults, hypertension is a leading cause of preventable morbidity and mortality. Both SBP and DBP increase linearly up to the fifth or sixth decade of life, after which DBP gradually decreases while SBP continues to rise. Thus, isolated systolic hypertension (ISH) is the predominant form of hypertension in older persons. But there's still no evidence whether elderly ISH patients would benefit from blood pressure and lipid lowering therapy.
- Objective: To demonstrate that blood pressure and lipid lowering therapy is effective and safe in elderly ISH patients.
- Study design: This is a 12-month prospective, randomized, active-controlled, apen-label, multi-center study, with three treatment groups: amlodipine/atorvastatin (5mg/10mg tablet); amlodipine (5mg tablet) and lifestyle intervention.
- Study population: Men or women aged between 65 and 79 years will be screened for hypertension. Eligible patients should be untreated patients with isolated systolic hypertension (clinic systolic blood pressure ≥ 130 and < 150mmHg), and diastolic blood pressure <80 mmHg). Patients should have abilities to understand the study requirements and provide informed consent.
- Randomization and treatment: After screening period by centers, eligible patients will be randomly divided into 3 groups, taking one pill of amlodipine/atorvastatin (5mg/10mg tablet) or amlodipine (5mg tablet) or lifestyle intervention only.
- Follow-up: After meeting the inclusion criteria, there will be 2-week screening period. Clinic blood pressure, ambulatory blood pressure, home blood pressure, electrocardiography, concomitant medication records and adverse event records will be collected at randomization period. Then patients will be randomly assigned into amlodipine/atorvastatin group and amlodipine group and lifestyle only group. The treatment will be observed for 12 months. There will be 6 visiting points in the treatment period, which will be the 1st month, 2nd month, 3rd month, 6th month, 9th month and 12th month.
- Sample size: A total of 480 patients should be enrolled in total.
- Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in October 2021, recruitment will start. Patients enrollment and follow-up will be performed between January 2022 to December 2023.
详细描述
- Study name: Blood Pressure and Lipids Reduction in High Risk Elderly Patients with Isolated Systolic Hypertension.
- Medicine: amlodipine/atorvastatin tablet (5mg/10mg) and amlodipine (5mg).
- Rationale: Because of its extremely high prevalence in older adults, hypertension is a leading cause of preventable morbidity and mortality. Both SBP and DBP increase linearly up to the fifth or sixth decade of life, after which DBP gradually decreases while SBP continues to rise. Thus, isolated systolic hypertension (ISH) is the predominant form of hypertension in older persons. But there's still no evidence whether elderly ISH patients would benefit from blood pressure and lipid lowering therapy.
- Objective: to demonstrate that blood pressure and lipid lowering therapy is effective and safe in elderly ISH patients.
- Study design: This is a 12-month prospective, randomized, active-controlled, apen-label, multi-center study, with three treatment groups: amlodipine/atorvastatin (5mg/10mg tablet); amlodipine (5mg tablet) and lifestyle intervention.
- Study population: men or women aged between 65 and 79 years will be screened for hypertension. Eligible patients should be untreated patients with isolated systolic hypertension (clinic systolic blood pressure ≥ 130 and < 150mmHg), and diastolic blood pressure <80 mmHg). Patients should have abilities to understand the study requirements and provide informed consent.
- Randomization and treatment: After screening period by centers, eligible patients will be randomly divided into 3 groups, taking one pill of amlodipine/atorvastatin (5mg/10mg tablet) or amlodipine (5mg tablet) or lifestyle intervention only.
- Follow up: after meeting the inclusion criteria, there will be 2-week screening period. Clinic blood pressure, ambulatory blood pressure, home blood pressure, electrocardiography, concomitant medication records and adverse event records will be collected at randomization period. Then patients will be randomly assigned into amlodipine/atorvastatin group and amlodipine group and lifestyle only group. The treatment will be observed for 12 months. There will be 6 visiting points in the treatment period, which will be the 1st month, 2nd month, 3rd month, 6th month, 9th month and 12th month.
- Sample size: A total of 480 patients should be enrolled in total.
- Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in October 2021, recruitment will start. Patients enrollment and follow-up will be performed between January 2022 to December 2023.
- Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 79 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 65-79;
- •Isolated systolic hypertension (office systolic blood pressure (SBP) ≥ 130 and < 150 mmHg and office diastolic blood pressure (DBP) < 80 mmHg) in untreated patients；
- •Ability to understand the study requirements and provide informed consent.
排除标准
- •Hypersensitivity history to any study drug or similar drug；
- •Severe renal insufficiency (eGFR < 30 mL/min/1.73m2);
- •Hyperkalemia (serum potassium > 5mmol/L);
- •Active liver disease or hepatic insufficiency (AST or ALT > 3 times upper limit of normal);
- •History of malignancy over the past 5 years;
- •Severe disease patients with life expectancy of < 1 year;
- •Previous or current diagnosis of heart failure;
- •Stroke or myocardial infarction within 6 months;
- •Previous or current atrial fibrillation, frequent ventricular premature beats, supraventricular tachycardia;
- •Patients who are receiving other study drugs or study medical devices;
- •Pregnant or lactating women;
- •Other circumstances that patients are not appropriate for the study upon the investigator's judgment.
研究组 & 干预措施
Amlodipine
Active Comparator
amlodipine (5mg QD)
干预措施: Amlodipine 5mg (Drug)
Lifestyle intervention
Other
干预措施: Lifestyle intervention (Other)
Amlodipine/atorvastatin
Experimental
amlodipine/atorvastatin (5mg/10mg QD)
干预措施: Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET (Drug)
结局指标
主要结局
Change in mean office systolic blood pressure after 12-month treatment from baseline in each group
时间窗: Baseline and 12 months
次要结局
- Difference in control rate of ambulatory blood pressure after 12-month treatment in each group(Baseline and 12 months)
- Change in ambulatory (24-h mean, daytime and nighttime) blood pressure after 12-month treatment from baseline in each group(Baseline and 12 months)
- Difference in control rate of clinic, ambulatory and home blood pressure after 6-month treatment in each group(Baseline and 6 months)
- Change in low-density lipoprotein cholesterol after 12-month treatment from baseline in each group(Baseline and 12 months)
- Change in mean office diastolic blood pressure after 12-month treatment from baseline in each group(Baseline and 12 months)
- Change in clinic, ambulatory and home mean blood pressure after 6-month treatment from baseline in each group(Baseline and 6 months)
- Difference in control rate of clinic and home blood pressure after 12-month treatment in each group(Baseline and 12 months)
研究者
Ji-Guang Wang
Director of the Shanghai Institute of Hypertension
Shanghai Jiao Tong University School of Medicine
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
4 期
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial FibrillationHypertensionAtrial FibrillationNCT04111419Shanghai Jiao Tong University School of Medicine1,200
尚未招募
4 期
Intensive lipid and blood pressure lowering and cardiovascular outcome: Randomised controlled trial on patients with coronary artery disease and type 2 diabetesJPRN-UMIN000003548Department of Clinical Pharmacology & Therapeutics, University of the Ryukyus Graduate School of Medicine1,000
已完成
不适用
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail ElderlyFrailtyOrthostatic IntoleranceCerebral HypoperfusionHypertensionOld Age DementiaOrthostatic HypotensionNCT05529147Radboud University Medical Center15
已完成
不适用
High blood pressure control and lipid lowering in patients at high cardiovascular risk: a cluster randomised factorial comparison of educational and protocol-based interventions to help primary care teams improve control of patients with poor risk factor controlTopic: Cardiovascular, Diabetes Research Network, Primary Care Research Network for EnglandSubtopic: Both, Not Assigned, Cardiovascular (all Subtopics)Disease: Diabetic Control, Cardiovascular, All DiseasesCirculatory SystemHigh cardiovascular riskISRCTN99472145William Harvey Research Institute (UK)10,000
已完成
2 期
Blood Pressure Reduction in Heart FailureCardiac FailureHeart FailureCongestive Heart FailureNCT01255475University of Sao Paulo21